both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on